Oaktree Acquisition Corp. III Life Sciences Files 8-K

TL;DR

Oaktree Acquisition Corp. III Life Sciences filed an 8-K on Dec 11, 2024. No major news yet.

AI Summary

Oaktree Acquisition Corp. III Life Sciences filed an 8-K on December 11, 2024, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transactions or financial results but serves as a notification of these items.

Why It Matters

This filing indicates that Oaktree Acquisition Corp. III Life Sciences has submitted required disclosures to the SEC, which may include updates on corporate events or financial information.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.

Key Players & Entities

• Oaktree Acquisition Corp. III Life Sciences (company) — Registrant
• December 11, 2024 (date) — Date of Report
• 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nsisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeema
• $11.50 — ordinary share at an exercise price of $11.50 OACCW The Nasdaq Stock Market LLC

Filing Documents

• d825014d8k.htm (8-K) — 19KB
• d825014dex991.htm (EX-99.1) — 10KB
• 0001193125-24-274894.txt ( ) — 30KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): December 11, 2024 Oaktree Acquisition Corp. III Life Sciences (Exact name of registrant as specified in its charter) Cayman Islands 001-42383 98-1799512 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 333 South Grand Avenue, 28th Floor Los Angeles, California 90071 (Address of principal executive offices) (Zip Code) +1 (213) 830-6300 (Registrants telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-fifth of one redeemable warrant OACCU The Nasdaq Stock Market LLC Class A ordinary shares included as part of the units OACC The Nasdaq Stock Market LLC Redeemable warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 OACCW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item8.01. Other Events On December 11, 2024, Oaktree Acquisition Corp. III Life Sciences (the Company) announced that the holders of the Companys units (the Units) may elect to separately trade the Class A ordinary shares, par value $0.0001 per share (the Class A ordinary shares), and warrants included in the Units commencing on December 16, 2024. Each Unit consists of one Class A ordinary share and one-fifth of one redeemable warrant to purchase one Class A ordinary share. Any Units not separated will continue to trade on the Nasdaq Global Market (Nasdaq) under the symbol OACCU. Any underlying Class A ordinary shares and warrants that are separated will trade on Nasdaq under the symbols OACC and OACCW, respectively. No fractional warrants will be issued upon separation of the Units and only whole warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Companys transfer agent, in order to separate their Units into Class A ordinary shares and warrants. A copy of the press release issued by the Company announcing the separate trading of the securities underlying the Units is attached hereto as Exhibit 99.1. Item9.01. Financial (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 11, 2024 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 11, 2024 OAKTREE ACQUISITION CORP. III LIFE SCIENCES By: /s/ Zaid Pardesi Name: Zaid Pardesi Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR